Association Between COVID-19 Vaccination and Neuropsychiatric Conditions

COVID-19 vaccine lipid nanoparticle (LNP) technology was
designed to facilitate delivery to all bodily tissues, including the
ability to cross natural barriers, such as the blood-brain barrier. The
Food and Drug Administration (FDA) issued its first Emergency Use
Authorization (EUA) for the Pfizer-BioNTech mRNA COVID-19
gene therapy product on December 11, 2020, followed one week
later by Moderna’s version. Although these experimental, non-
traditional "vaccines" were classified as vaccines under a new CDC
definition, they contained a degradation-resistant mRNA sequence
coding for a single COVID-19 viral antigen, known as the spike
protein. The spike protein can cross the blood-brain barrier through
vascular damage and exhibit pathological activity, while both the
LNPs and the spike protein are highly inflammatory. It is also known
that the mRNA for the spike protein can be expressed in the brain
following both a natural infection and, particularly, after repeated
COVID-19 mRNA “vaccinations” .In conclusion, there are unprecedented safety signals indicating an
association between COVID-19 vaccination and the development of
neuropsychiatric disorders. The effects of these biological products
on maternal and fetal health are of great concern [40,41]. Our findings
are worrisome for the future population risk for a variety of
neuropsychiatric disorders including those affecting cognition and
suicidal/homicidal behaviors. Additionally, population intelligence
should be thoroughly assessed among vaccinated and unvaccinated
groups. In the meantime, the COVID-19 vaccines should be
immediately withdrawn from the market.